Toni Choueiri reports preliminary results from the FRACTION-RCC study showing encouraging efficacy of nivolumab plus ipilimumab in advanced renal cell carcinoma patients who have progressed on prior immunotherapy (3:11).
This independent video interview was supported by an educational grant from Pfizer and Merck KGaA